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toxicity profiles depending on the size and location of 
metastatic sites. Clinical data indicate that the number of 
patients with oligometastatic disease receiving aggressive 
treatments is increasing rapidly. The distinct biological 
behavior of tumors with oligometastatic spread is currently 
explored by a number of groups. 
The most robust verification of ablative oligometastasis-
directed therapy has been documented in patients with 
limited intracranial metastases for which systemic treatment 
had limited efficacy. Randomized studies have demonstrated 
that surgical resection or radiosurgery can improve overall 
survival when added to whole-brain irradiation. Randomized 
evidence also exists for surgical resection of metastases, not 
solely in patients with oligometastases, causing epidural 
spinal cord compression. Outside of the central nervous 
system, limited randomized evidence exists to guide 
therapeutic decisions for patients with oligometastases. Most 
practice patterns are guided by large, single-institution or 
pooled series of patients demonstrating favorable survival. 
Limited number of studies with adequate controls raise the 
possibility that this survival gain might not be due to 
treatment effect, but rather due to patient selection 
criteria. For the widespread acceptance of oligometastatic 
ablative treatment, stronger evidence supporting its efficacy 
is needed. 
 
Oligo- and hypofractionated stereotactic radiotherapy of 
lung cancer 
R. Dziadziuszko 
Dept. of Oncology and Radiotherapy, Medical University of 
Gdańsk, Poland 
 
As a result of two decades of research, hypofractionated 
stereotactic radiotherapy of stage I non-small cell lung 
cancer (NSCLC) is now established as a standard of care in 
patients who are not candidates for surgical treatment. As 
demonstrated in large series of patients treated with SBRT 
for NSCLC, locoregional control exceeds 80% at 5-years, 
which appears comparable to surgical outcomes. SBRT 
programs became available in most European countries and 
centers, including several institutions in Poland. 
Implementation of successful SBRT program must focus on 
4D-CT imaging, co-registered with repeatable breath cycle, 
careful GTV and PTV delineation taking into account 
respiratory motion, treatment planning using advanced B-
type algorithms  by experienced physicists, image guided 
treatment delivery, and implementation of strict quality 
control measures. Most common treatment schedules include 
54Gy in 3 fractions, 55Gy in 5 fractions and 60Gy in 8 
fractions, depending on tumor location and proximity of 
organs-at-risk. Current research efforts exploring SBRT for 
lung cancer include clinical trials in patients who are 
considered for surgery, management of centrally located 
tumors, clinical and radiological patterns of disease 
recurrence, clinical and molecular prognostic factors and 
assessment of systemic therapies, including immunotherapies 
and targeted agents. Other studies evaluate the addition of 
SBRT as a boost to conventionally fractionated 
radiochemotherapy for stage II – III NSCLC. 
 
SBRT of liver tumors 
R. Suwinski 
M. Sklodowska-Curie Memorial Cancer Center and Institute 
of Oncology, Gliwice Branch, Poland 
 
Only relatively small proportion of hepatic tumors can be 
safely resected. Modern radiation treatment techniques can 
enhance, thus, therapeutic options beyond palliative 
systemic treatment or other local ablative techniques. The 
data from the literature indicate that stereotactic body 
radiation therapy (SBRT) can offer satisfactory rate of local 
control both in primary hepatocellular cancer (HCC) or liver 
metastases (LM). Total radiation dose  of 45 Gy or more and 
target diameter of less than 5 cm are among the factors 
related to favorable local control. Review of the published 
data indicate that local control at 1-2 years can, in general, 
exceed 70% in properly selected groups of patients. 
Respiratory motion of the liver provides a challenge in 
delivery of high radiation dose to the tumor demanding 
expansion of irradiated volume to encompass movements of 
the tumor. To address this problem special radiation 
techniques are used including respiratory gating, tracking or 
abdominal compression. Such techniques allow to minimize 
the margins and reduce, thus, the dose delivered to the 
normal tissue that surrounds the tumor. In spite of high local 
control rates overall survival of patients with hepatic tumors 
treated with SBRT is not satisfactory, mostly because of 
distant failures. This illustrates urgent need to develop new 
treatment strategies that would better integrate available 
local and systemic therapies. 
 
CyberKnife for prostate cancer patients – preliminary 
results of 200 patients irradiation. 
L. Miszczyk, A. Namysł-Kaletka, A. Napieralska, G. Głowacki, 
K. Grabińska 
Radiotherapy Department, Cancer Center and Institute of 
Oncology, Gliwice branch, Poland 
 
Introduction: Prostate cancer (PC) is one of most common 
malignancies. Large percentage of PC patients is treated with 
radiotherapy (RT). The main problem connected to 
conventional radiotherapy is long overall treatment time 
(OTT) ranging to 8 weeks, so many attempts of OTT shrinkage 
are done. The one of them is CyberKnife based radioablation 
allowing to complete the therapy within 5-9 days. 
Material: 200 PC patients aged from 53 to 83 (mean 69)  
irradiated every other day using fd of 7.25 Gy to TD of 36.25 
Gy (OTT 9 days). 95 were from low risk, 104 from 
intermediate risk (excluding Gleason 4+3) and 1 from high 
risk group. The maximal PSA varied from 1.05 to 50.3 (mean 
8.6, median 7.6). T stage varied from T1c to T2c. Means of 
prostate dimensions before the treatment were 
42.5x37.5x40.4 mm for X, Y and Z axes respectively. 
Method: After treatment completion, 1, 4, 8 months later 
and next every each 6 months up to 26 months the 
percentage of patients using hormonal drugs (HT), GI (gastro-
intestinal) and GU (genito-urinary) toxicity using 
EORTC/RTOG scale (acute up to 4th month and next late) and 
PSA were checked. 
Results: Results obtained during FU are presented in the 
Table. 
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 RT 
end 
1 
mth 
4 
m. 
8 
m.  
14 
m. 
20 
m. 
26m
. 
N of 
pts. 
200 142 166 150 117 41 17 
No HT 
[%] 
45 65.5 75.9 80.7 86.3 85.4 94.1 
GI 0 
[%] 
86.4 89.4 91.5 92.1 97.5 100.
0 
100.
0 
GI 1 
[%] 
13.1 8.5 6.7 7.3 2.5 - - 
GI 2 
[%] 
0.5 2.1 1.2 0.6 - - - 
GI 3 
[%] 
- - 0.6 - - - - 
GU 0 
[%] 
69.8 62.7 87.8 93.4 88.2 98.0 94.4 
GU 1 
[%] 
20.1 32.4 10.4 6.0 8.4 2.0 5.6 
GU 2 
[%] 
9.1 4.2 1.8 0.6 3.4 - - 
GU 3 
[%] 
1.0 0.7 - - - - - 
PSA 
range 
[ng/m
l] 
0.00
8- 
15,2 
0.00
8- 
16.3 
0.02
- 
5.7 
0.00
- 
6.4 
0.00
2- 
6.3 
0.00
8- 
6.3 
0.01
- 
10.0 
PSA 
mean 
4.0 2.0 1.1 0.7 0.5 0.5 0.9 
PSA 
media
n 
3.4 1.0 0.4 0.3 0.2 0.2 0.1 
 
During FU one patient had confirmed relapse (18 month after 
RT) – (Phoenix+biopsy) and was treated with salvage BT. 
 Conclusion: Obtained results permit us to form conclusion 
that CK based radioablation of low and intermediate risk PC 
patients is an effective treatment modality allowing for OTT 
shrinkage and significant reduction of adverse effects. 
 
Can SRT preserve TCP of HNC patient when standard 
therapy is not compliant? 
Ł Michalecki, K Skladowski 
1st Radiation and Clinical Oncology Department, The Institute 
of Oncology – MSCCC in Gliwice 
 
Not compliant RT of HNC patient is usually understood as a 
violation of dose-time parameters of less or more than 10%, 
respectively. For the purpose of this study:  
A. the overall treatment time (OTT) prolonged more 
than 5 days due to gap(s) in RT is recognized as a 
non-compliant;  
B. original radiobiological explanation hypothesis of 
Gap-Position Phenomenon (GPP) discovered by 
Skladowski K. et al. 1994, 1998) is proposed;  
C. TCP rates are estimated according to Fowler 
methodology. 
Ad A. During current conventional fractionation RT about 10-
15% of patients have experienced the significant prolongation 
of OTT. All these are happen due to and have taken in 
average: random reasons (55%) 5 days, unexpected toxicity 
(20%) 10 days and co-morbidity (25%) 20 days. The average 
length of any gap is 7 days. 
Ad B. For early gap, i.e. 1-19th day of OTT: proangiogenic 
effect of low (<30 Gy) RT dose delivered before the gap is 
evident, therefore reoksygenation of primary tumor hypoxic 
fraction is very expected in spite of evident tumor shrinkage 
due to cell kill of oxic fraction. We hypothesized recruitment 
and repopulation of tumor clonogens over the gap and 
number of tumor cells to kill has increased. As a 
consequence, decreased radiosensitivity is observed when RT 
has returned = loss of LC. For mid gap, i.e. 20-26th day (1 
week only): effect of vascular normalization of 30-40 Gy RT 
dose delivered before the gap is possible and could enhanced 
reoxygenation of residual hypoxic fraction over the gap, what 
means radiosensitivity is increased when RT has returned = 
equal or increased LC. For late gap, i.e. after 26th day: 
effect of vascular damage of high (>40 Gy) RT dose delivered 
before the gap is evident and all residual, alive tumor cells 
become hypoxic, where majority of them are stem allowed to 
fast repopulation over the gap when reoxygenation is possible 
(or later after the treatment completion, if they survive), 
therefore radiosensitivity is decreased when RT has returned 
= loss of LC. From these points of view we should to observe 
clinically different pattern of tumor failures - the rates of 
uncompleted responses (UR) and relapses after complete 
response, and, perhaps, speed of relapse occurrence. 
Ad C. According to Fowler methodology our modeling is 
convinced that SRT could restore the TCP of OTT-protracting 
standard fractionated treatment in aspect of early and late 
gap. 
 
Will SRT be a standard method of malignant tumors? 
K. Skladowski1, R. Dziadziuszko2, L. Miszczyk1, K. Ślosarek1, 
M. Janiszewska3, T. Piotrowski4, R. Suwiński1, B. Maciejewski1 
1Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie 
Oddział w Gliwicach,  
2 Klinika i Zakład Radioterapii Gdańskiego Uniwersytetu 
Medycznego,  
3Zakład Fizyki Medycznej Dolnośląskiego Centrum Onkologii 
we Wrocławiu,  
4Zakład Fizyki Medycznej Wielkopolskiego Centrum Onkologii 
w Poznaniu 
 
At the present time, published clinical results on SBRT exist 
for the following indications: early-stage lung cancer in 
medically inoperable patients or those refusing surgery, lung 
metastases from a large variety of primary cancers, primary 
liver cancer in medically inoperable patients, liver 
metastases (as with lung metastases), pancreas cancer, 
adrenal metastases, primary kidney cancer in medically 
inoperable patients, organ-confined prostate cancer, 
selected intra-thoracic and intra-abdominal lymph node 
metastases, recurrent and primary head and neck cancers, 
spinal tumors, and vertebral bone metastases. Of special 
interest is the current use of SBRT in prostate cancer, where 
patients enjoy high cure rates with a variety of well-
tolerated existing therapies. In this context, especially for 
low-risk patients, the introduction of high-potency SBRT 
could constitute a threat to good outcome in a disease where 
improvements in both disease-free survival and tolerance are 
unlikely. Yet existing treatments are far from perfect. For 
example, conventionally fractionated high dose intensity-
modulated radiation therapy is both expensive for payers and 
inconvenient for patients. Numerous reports with limited 
follow-up show that 5-fraction SBRT for low-risk prostate 
cancer positively addresses both complaints. Using dose 
regimens that are less potent than those used for tumors in 
other sites, prostate SBRT results in excellent clinical 
outcomes compared with other standard treatments in a 
convenient and cost-effective manner. Would SBRT/SRT 
become a standard irradiation method for radiocurable 
tumors and what should they have a bio-clinical 
characteristics? 
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